PHAT Phantom Pharma to moonshot from upgrade LONG
Zaktualizowano
PHAT is now targeting 25-34 according to analysts. I am not surprised. It has a pipeline and
is pending approval for a medication product to treat a stomach bacteria that causes chronic
infection and symptoms are often refractory to long and elaborate treatment protocols. The
product is already in Asia and doing well in YoY reports. PHAT has partnered with another
pharma company to make regulatory and marketing inroads in the European market. My
portfolio is already heavy with medtech and pharma but this one is far to promising
with the great upside it presents. I will hit this one hard trying to get the low of day in
pieces and build a position.
is pending approval for a medication product to treat a stomach bacteria that causes chronic
infection and symptoms are often refractory to long and elaborate treatment protocols. The
product is already in Asia and doing well in YoY reports. PHAT has partnered with another
pharma company to make regulatory and marketing inroads in the European market. My
portfolio is already heavy with medtech and pharma but this one is far to promising
with the great upside it presents. I will hit this one hard trying to get the low of day in
pieces and build a position.
Komentarz
NEWS and Analysis seekingalpha.com/article/4480460-phathom-pharmaceuticals-phat-undiscovered-gemKomentarz
stocktwits.com/symbol/PHATKomentarz
Investor Relations investors.phathompharma.com/
Komentarz
Science phathompharma.com/our-science/Komentarz
Tip Ranks markets.businessinsider.com/news/stocks/positive-prescription-trends-and-resilience-prompt-buy-rating-for-phathom-pharmaceuticals-1033189695Komentarz
Back up the truck and tell your friends you would like to borrow their truck for a day or two .....Komentarz
Wyłączenie odpowiedzialności
Informacje i publikacje przygotowane przez TradingView lub jego użytkowników, prezentowane na tej stronie, nie stanowią rekomendacji ani porad handlowych, inwestycyjnych i finansowych i nie powinny być w ten sposób traktowane ani wykorzystywane. Więcej informacji na ten temat znajdziesz w naszym Regulaminie.